Rocket Pharmaceuticals Inc Stock News

Rocket Pharmaceuticals Inc (RCKT) shares surged 32% in pre-market trading on Wednesday after the biotechnology company developing gene therapy announced that it has reached an agreement with the US Fo

Rocket Pharmaceuticals is developing gene therapies for rare diseases, with positive results and safety profiles from clinical trials. The company's financial performance includes $360 million in cash

A small-cap stock is a security whose market capitalization ranges between $250 million and $2 billion. Small-cap stocks are often companies that are relatively small and focused on a niche business.

The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. The stock gains 2.3% following the news.

Shares of Rocket Pharmaceuticals RCKT, +0.17% gained 2.3% premarket on Thursday after the late-stage biotech company said the U.S. Food and Drug Administration granted fast-track and orphan-drug desig

Today, we peek back in on Rocket Pharmaceuticals, Inc. for the first time in 2023. The company is seeing some momentum from positive trial developments and new-found enthusiasm from the analyst commun

Rocket Pharmaceuticals stock trades at ~$19.5 today - back in December 2021 it had hit highs of >$60. The highs were achieved when Rocket's in vivo gene therapy showed promise treating patients with a

Rocket Pharmaceuticals, Inc. performed beautifully for me in the last half year. They have a number of catalysts in the next few months.

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rar

A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. A regulatory filing to the FDA of LV RP-L102 for Fanc

Shares of gene therapy concern Rocket Pharmaceuticals have fallen 75% from their all-time high set in February 2021 with the only setback a three-month hold on one clinical trial. Although the company

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 211.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

Shares have lost 15% year to date. Company wisely adopted a platform-agnostic approach to address first-in-class opportunities across the gene therapy pipeline.

Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up 2.